Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Multicenter Observational Study on Recurrence Patterns and Health Care Resource Utilization in Stage II Cutaneous Melanoma in Spain: Real-world Evidence From the METHEOR Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2023 · External reference
Unresolved reference
2022 · External reference
SEOM clinical guideline for the management of cutaneous melanoma (2020)
10.1007/s12094-020-02539-9 · 2021 · External reference
Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study
10.1016/j.ejca.2020.11.036 · 2021 · External reference
Melanoma prognosis: accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition
10.1093/jnci/djaa008 · 2020 · External reference
Recurrence patterns in patients with Stage II melanoma: the evolving role of routine imaging for surveillance
10.1002/jso.26214 · 2020 · External reference
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?
10.1111/bjd.17145 · 2018 · External reference
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2024.11.006 · 2025 · External reference
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
10.1038/s41591-023-02583-2 · 2023 · External reference
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study
10.1200/jco.2023.41.17_suppl.lba9505 · 2023 · External reference
Patient symptoms are the most frequent indicators of recurrence in patients with American Joint Committee on Cancer Stage II Melanoma
10.1016/j.jamcollsurg.2016.12.038 · 2017 · External reference
Patterns and timing of initial relapse in pathologic stage II melanoma patients
10.1245/s10434-016-5642-0 · 2017 · External reference
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
10.1016/0021-9681(87)90171-8 · 1987 · External reference
Unresolved reference
2017 · External reference
Estudio descriptivo de costes en melanoma cutáneo de diferentes estadios
10.1016/j.ad.2016.09.010 · 2017 · External reference
Unresolved reference
External reference
Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment
10.1200/jco.22.00202 · 2022 · External reference
Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
2017 · External reference
Risk factors for lymphatic and hematogenous dissemination in patients with stages I to II cutaneous melanoma
10.1001/jamadermatol.2019.0069 · 2019 · External reference
Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis
10.1097/00008390-200506000-00005 · 2005 · External reference
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
10.1016/s1470-2045(21)00065-6 · 2021 · External reference
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
10.1056/nejmoa1910836 · 2019 · External reference
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
10.1056/nejmoa1709030 · 2017 · External reference
Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K)
10.25251/skin.7.supp.163 · 2023 · External reference
Sentinel lymph node biopsy in cutaneous melanoma – where do we stand?
10.1001/jamadermatol.2021.3048 · 2021 · External reference
Melanoma incidence, recurrence, and mortality in an integrated healthcare system: a retrospective cohort study
10.1002/cam4.2252 · 2019 · External reference
Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma
10.1111/ijd.15939 · 2022 · External reference
Real-world recurrence rates and economic burden in patients with resected early-stage melanoma
10.1007/s13555-020-00404-9 · 2020 · External reference
The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031
10.1016/j.jid.2016.01.035 · 2016 · External reference
